Search results for "Apolipoprotein E4"

showing 9 items of 19 documents

Association between mid- to late life physical fitness and dementia: Evidence from the CAIDE study

2014

Objectives. This study investigated the association between perceived physical fitness at midlife, changes in perceived fitness during the three decades from mid-to late life and dementia risk. Design. Prospective cohort study. Setting. Cardiovascular risk factors, ageing and incidence of dementia (CAIDE) study. Subjects. Subjects were selected from four independent, random samples of population-based cardiovascular surveys and were first examined in 1972, 1977, 1982 or 1987, when they were on average 50 years old. The CAIDE target population included 3559 individuals. A random sample of 2000 individuals still alive in 1997 was drawn for re-examinations (performed in 1998 and 2005-2008) tha…

GerontologyMalePhysical fitnessPopulationApolipoprotein E4ta3112Internal MedicineMedicineDementiaHumansProspective StudiesSex DistributionProspective cohort studyeducationta315Agededucation.field_of_studybusiness.industryIncidence (epidemiology)Hazard ratiota3141Odds ratiota3142Middle Agedta3121medicine.diseaseConfidence intervalSelf ConceptPhysical FitnessDementiaFemaleSedentary BehaviorbusinessJournal of Internal Medicine
researchProduct

Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease.

2006

OBJECTIVE: There have been inconclusive results to date on the association between the Apolipoprotein E (ApoE) genotype and neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD). We investigated whether ApoE epsilon4 allele is associated with NPS in probable AD. METHOD: Data for 197 subjects with probable AD were analysed. The Neuropsychiatric Inventory was used to evaluate the frequency and severity of NPS. Multiple logistic regression models were used to test the association between ApoE genotype and NPS in AD. RESULTS: The ApoE epsilon3/3 genotype was present in 52.3%, epsilon3/4 in 44.1%, and epsilon4/4 in 3.6% of patients. ApoE epsilon4 carriers showed a higher frequency of apath…

MaleApolipoprotein EGenotypeApolipoprotein E4DiseaseNeuropsychological TestsSeverity of Illness IndexApolipoproteins EDegenerative diseaseAlzheimer Diseasemental disordersGenotypemedicineHumansDementiaApathyAllelebehavioural symptomAllelesAgedapolipoprotein EMood DisordersAlzheimer's diseasemedicine.diseasePsychiatry and Mental healthImmunologyFemalelipids (amino acids peptides and proteins)Settore MED/26 - NeurologiaAlzheimer's diseasemedicine.symptomPsychologyNeurosciencelogistic modelsdementia
researchProduct

Apoe genotypes and brain imaging classes in normal cognition, mild cognitive impairment, and alzheimer’s disease: A longitudinal study

2020

Objective: To evaluate in 419 stroke-free cognitively normal subjects (CN) aged 45-82 years covering during a long prospective study (11.54 ± 1.47 years) the preclinical to dementia spectrum: 1) the distribution of small vessel disease (V) and brain atrophy (A) aggregated as following: V−/A−, V−/A+, V+/A−, V+/A+; 2) the relationship of these imaging classes with individual apolipoprotein E (APOE) genotypes; 3) the risk of progression to Alzheimer Disease (AD) of the individual APOE genotypes. Methods: Participants underwent one baseline (t0), and 4 clinical and neuropsychological assessments (t1,t2,t3, and t4). Brain MRI was performed in all subjects at t0, t2, t3 and t4.. White matter hyp…

MaleApolipoprotein Emedicine.medical_specialtyGenotypeApolipoprotein E4NeuroimagingNeuropsychological TestsAPOE genotypes Brain imaging classes Caudate atrophy Global cerebral atrophy Lacunes White matter hyperintensities Aged Aged 80 and over Alzheimer Disease Apolipoprotein E4 Apolipoproteins E Brain Case-Control Studies Cognitive Dysfunction Disease Progression Female Genotype Humans Longitudinal Studies Magnetic Resonance Imaging Male Middle Aged Neuroimaging Neuropsychological Tests Risk Factorsbrain imaging classesApolipoproteins EAtrophyNeuroimagingAlzheimer DiseaseRisk FactorsInternal medicineGlobal brain atrophymedicineHumansDementiaCognitive DysfunctionLongitudinal Studiescaudate atrophyAgedglobal cerebral atrophyAged 80 and overAPOE genotypesbusiness.industryNeuropsychologyBrainMiddle Agedwhite matter hyperintensitiesmedicine.diseaseMagnetic Resonance ImagingHyperintensityNeurologyCase-Control StudiesDisease ProgressionCardiologyFemaleNeurology (clinical)Alzheimer's diseasebusiness
researchProduct

Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions

1999

In recent research, apolipoprotein-E (apoE) polymorphism has been shown to influence the formation of neurofibrillary changes and the accumulation of beta/A4-amyloid, the histopathological hallmarks of Alzheimer's disease (AD). Clinical studies associate the apoE allele epsilon4 with earlier onset of the disease, although the clinical speed of progression remains unchanged. Time course estimates have also provided evidence which indicates that the clinical phase of AD constitutes only 10-20% of the total time span needed for the development of this slowly progressing degenerative brain disorder. Due to the lack of reliable clinical tests for the detection of pre-symptomatic stages of AD, we…

MaleApolipoprotein Emedicine.medical_specialtyPathologyGenotypeApolipoprotein BApolipoprotein E2Apolipoprotein E4Apolipoprotein E3tau ProteinsNeuropathologyPathology and Forensic MedicineCellular and Molecular NeuroscienceApolipoproteins EDegenerative diseaseIsomerismAlzheimer DiseaseInternal medicineGenotypemedicineHumansAlleleAllelesBrain ChemistryAmyloid beta-PeptidesPolymorphism GeneticbiologyBrainNeurofibrillary TanglesNeurofibrillary tangleMiddle Agedmedicine.diseaseEndocrinologyDisease Progressionbiology.proteinFemaleNeurology (clinical)Alzheimer's diseaseActa Neuropathologica
researchProduct

The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population.

2011

Objective: To investigate the symptom of low mood as a predictor of mild cognitive impairment (MCI) and its progression to dementia, taking into account: i) MCI severity, ii) time of assessment, iii) interaction with other factors. Methods: 764 cognitively healthy elderly living in the community, from the Kungsholmen Project. Participants were assessed by direct interview to detect low mood. Subjects were then followed for six years to identify those who developed MCI. People with incident MCI were followed for a further three years to assess progression to dementia. Results: People with low mood at baseline had a 2.7-fold (95% Confidence Interval [CI] 1.9-3.7) increased risk of developing …

MaleDatabases FactualApolipoprotein E4behavioral disciplines and activitiesProdromeCohort Studiesmild cognitive impairmentmental disordersmedicinedepression; epidemiology; mild cognitive impairment; dementiaDementiaHumansCognitive declineAgedSex CharacteristicsMood DisordersCognitive disorderProdromal StageCognitionmedicine.diseaseDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthMoodData Interpretation StatisticaldepressionDisease ProgressionEducational StatusRegression AnalysisSurgeryepidemiologySettore MED/26 - NeurologiaDementiaFemaleNeurology (clinical)AmnesiaPsychologyCognition DisordersCohort studyClinical psychologyFollow-Up StudiesJournal of neurology, neurosurgery, and psychiatry
researchProduct

Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP

2010

Objective To report the clinical, genetic, neuroimaging, and neuropathologic studies of patients with the hereditary cerebral hemorrhage with amyloidosis linked to the APP E693K mutation. Design Case series. Clinical details and laboratory results were collected by direct evaluation and previous medical records. DNA analysis was carried out in several affected subjects and healthy individuals. Neuropathologic examination was performed in 2 subjects. Setting Southern Lombardy, Italy. Patients Individuals with and without amyloidosis in 4 unrelated Italian families (N = 37). Main Outcome Measure Genotype-phenotype relationship. Results The affected individuals presented with recurrent headach…

MalePathologymedicine.medical_specialtySubarachnoid hemorrhageGenotypeApolipoprotein E4Glutamic AcidNeuropathologyAmyloid beta-Protein PrecursorGene FrequencyArts and Humanities (miscellaneous)medicineHumansGenetic Predisposition to DiseaseCognitive declineAgedCerebral HemorrhageFamily HealthAmyloid beta-Peptidesbusiness.industryLysineAmyloidosisLeukoaraiosisAutosomal dominant traitMiddle Agedmedicine.diseaseMagnetic Resonance ImagingPeptide FragmentsItalyHemosiderinMutationHereditary cerebral hemorrhage with amyloidosisFemaleNeurology (clinical)businessAmyloidosis FamilialGenome-Wide Association Study
researchProduct

Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

2011

Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers of Alzheimer's disease (AD). We examined the agreement between these biomarkers in a single center study of patients with AD of severity extending over a wide range. Forty seven patients (MMSE 21.4 ± 3.6, range 13-28 points) with incipient and probable AD underwent positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) and lumbar puncture for CSF assays of Aβ1-42, p-tau181, and t-tau. All findings were classified as either positive or negative for AD. Statistical analyses were performed for the whole samp…

Malemedicine.medical_specialtyPathologyAmyloid betaApolipoprotein E4tau ProteinsNeuropsychological TestsGastroenterologySensitivity and SpecificityCerebrospinal fluidAlzheimer DiseaseFluorodeoxyglucose F18Internal medicinemental disordersmedicineDementiaHumansAgedRetrospective StudiesPsychiatric Status Rating ScalesAmyloid beta-Peptidesmedicine.diagnostic_testbiologyLumbar punctureNeurodegenerationCerebrospinal Fluid ProteinsMiddle Agedmedicine.diseasePeptide FragmentsNeurologyPositron emission tomographyArea Under CurvePositron-Emission Tomographybiology.proteinFemaleNeurology (clinical)Alzheimer's diseasePsychologyCognition DisordersKappaBiomarkersFollow-Up StudiesCurrent Alzheimer research
researchProduct

Genes, Ageing and Longevity in Humans: Problems, Advantages and Perspectives.

2006

Many epidemiological data indicate the presence of a strong familial component of longevity that is largely determined by genetics, and a number of possible associations between longevity and allelic variants of genes have been described. A breakthrough strategy to get insight into the genetics of longevity is the study of centenarians, the best example of successful ageing. We review the main results regarding nuclear genes as well as the mitochondrial genome, focusing on the investigations performed on Italian centenarians, compared to those from other countries. These studies produced interesting results on many putative "longevity genes". Nevertheless, many discrepancies are reported, l…

Mitochondrial DNAAgingProteasome Endopeptidase ComplexNuclear geneApolipoproteins geneticsInsulin-Like Growth Factor I geneticsmedia_common.quotation_subjectApolipoprotein E4LongevityBiologyGenetic polymorphisms ageing longevity centenarians association studies mitochondrial DNABiochemistryDNA MitochondrialInflammation geneticsApolipoprotein E4 geneticsCytokines geneticsAnimalsHumansAlleleInsulin-Like Growth Factor ILongevity geneticsGenemedia_commonGenetic associationGeneticsAged 80 and overInflammationPolymorphism GeneticAryldialkylphosphataseSuperoxide DismutaseLongevitySuperoxide Dismutase geneticsGeneral MedicineClusterin geneticsPoly(ADP-ribose) Polymerases geneticsAging geneticsApolipoproteinsClusterinTumor Suppressor Protein p53 geneticsGenesEvolutionary biologyTraitCytokinesGene poolPoly(ADP-ribose) PolymerasesTumor Suppressor Protein p53Aryldialkylphosphatase geneticsDNA Mitochondrial geneticsProteasome Endopeptidase Complex physiology
researchProduct

Mild cognitive impairment: A systematic review

2007

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI ( aMCI) characterized by reduced memory, and non- amnestic MCI ( naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous - including vascular dementia, frontotemporal dementia or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classifi…

medicine.medical_specialtyApolipoprotein E4Neuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activitiesPhysical medicine and rehabilitationNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Risk Factorsmental disordersEpidemiologySeverity of illnessmedicineHumansDementiaVascular dementiaapolipoprotein EAlzheimer disease; apolipoprotein E; biomarkers; diagnosis; mild congnitive impairmentMemory Disordersbusiness.industryDementia VascularGeneral NeuroscienceBrainCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingmild congnitive impairmentdiagnosiPsychiatry and Mental healthClinical PsychologyEtiologybiomarkerSettore MED/26 - NeurologiaRadiopharmaceuticalsGeriatrics and GerontologyCognition DisordersbusinessFrontotemporal dementia
researchProduct